Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia

BACKGROUND: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO‐B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1 mg of ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Dawn C., Ritter, Aaron, Thomas, Ronald G., Andrews, Randolph D., Lukic, Ana S., Revta, Carolyn, Kinney, Jefferson W., Tousi, Babak, Leverenz, James B., Fillit, Howard, Zhong, Kate, Feldman, Howard H., Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882538/
https://www.ncbi.nlm.nih.gov/pubmed/33614888
http://dx.doi.org/10.1002/trc2.12106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882538/
https://www.ncbi.nlm.nih.gov/pubmed/33614888
http://dx.doi.org/10.1002/trc2.12106

Ejemplares similares